Drug Profile
Ferric maltol - Shield Therapeutics
Alternative Names: Accrufer; Feraccru; Iron (III) maltol; ST-10; ST10-021Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator University of Cambridge; University of London
- Developer KYE Pharmaceuticals; Shield Therapeutics
- Class Antianaemics; Ferric compounds; Pyrones; Small molecules
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Iron deficiency anaemia
Most Recent Events
- 28 Mar 2022 Preregistration for Iron deficiency anaemia in Canada (PO)
- 23 Mar 2022 KYE Pharmaceuticals submits a New Drug Submission to Health Canada for the regulatory review and approval of ferric maltol (Accrufer®) for the treatment of Iron deficiency anemia
- 21 Mar 2022 KYE Pharmaceuticals anticipates marketing approval for Accrufer® during the first half of 2023